ASCO26: Data highlights test benefit in breast cancer treatment planning and earlier detection
Findings from a study of Veracyte’s Prosigna genomic assay and GRAIL’s multi-cancer early detection test were presented at ASCO 2026.
01 June 2026
01 June 2026
Findings from a study of Veracyte’s Prosigna genomic assay and GRAIL’s multi-cancer early detection test were presented at ASCO 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.